In last trading session, Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) saw 0.38 million shares changing hands with its beta currently measuring 2.34. Company’s recent per share price level of $63.76 trading at $0.79 or 1.25% at ring of the bell on the day assigns it a market valuation of $4.05B. That closing price of RYTM’s stock is at a discount of -7.56% from its 52-week high price of $68.58 and is indicating a premium of 44.84% from its 52-week low price of $35.17. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.72 million shares which gives us an average trading volume of 665.98K if we extend that period to 3-months.

For Rhythm Pharmaceuticals Inc (RYTM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.68 in the current quarter.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) trade information

Upright in the green during last session for gaining 1.25%, in the last five days RYTM remained trading in the green while hitting it’s week-highest on Friday, 04/25/25 when the stock touched $63.76 price level, adding 0.38% to its value on the day. Rhythm Pharmaceuticals Inc’s shares saw a change of 13.90% in year-to-date performance and have moved 3.27% in past 5-day. Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) showed a performance of 17.42% in past 30-days. Number of shares sold short was 4.66 million shares which calculate 8.42 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 70 to the stock, which implies a rise of 8.91% to its current value. Analysts have been projecting 64 as a low price target for the stock while placing it at a high target of 80. It follows that stock’s current price would drop -0.38% in reaching the projected high whereas dropping to the targeted low would mean a loss of -0.38% for stock’s current value.

Rhythm Pharmaceuticals Inc (RYTM) estimates and forecasts

This year revenue growth is estimated to rise 41.00% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 40.16M for the same. And 11 analysts are in estimates of company making revenue of 44.2M in the next quarter. Company posted 25.97M and 29.08M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.34% during past 5 years.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM)’s Major holders

Insiders are in possession of 0.54% of company’s total shares while institution are holding 107.87 percent of that, with stock having share float percentage of 108.46%. Investors also watch the number of corporate investors in a company very closely, which is 107.87% institutions for Rhythm Pharmaceuticals Inc that are currently holding shares of the company. PRIMECAP MANAGEMENT CO/CA/ is the top institutional holder at RYTM for having 7.31 million shares of worth $300.25 million. And as of 2024-06-30, it was holding 11.9852 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 6.74 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.0502 of outstanding shares, having a total worth of $276.82 million.

On the other hand, PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 4.45 shares of worth $283.56 million or 7.03% of the total outstanding shares. The later fund manager was in possession of 1.9 shares on Dec 31, 2024 , making its stake of worth around $121.23 million in the company or a holder of 3.01% of company’s stock.